BALAXI PHARMACEUTICALS LIMITED — Important, 10-02-2025: Updates

Balaxi Pharmaceuticals has been notified of multiple instances of non-compliance with Listing Regulations, resulting in a total fine of ₹1,59,300, which includes ₹24,300 in GST. These violations pertain to Regulation 17(1) for the quarter ending September 30, 2024, with continuing fines accruing daily until compliance is met. The company must ensure that its Board discusses these compliance issues in the next meeting and report back to the National Stock Exchange. With a potential risk of further penalties and operational disruptions if non-compliance persists, investors should watch closely for the company’s response and any future regulatory actions.